Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk

Provided By PR Newswire

Last update: Nov 18, 2021

MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.